Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $224K | $329K | $430K | $283K | $239K | $191K | $65.4K | — | $43.5M | $312M |
| Revenue growth | — | 47.0% | 30.5% | -34.1% | -15.5% | -20.2% | -65.7% | — | — | 617.0% |
| Gross profit | -$143K | $214K | $33.0K | -$90.0K | $34.4K | $42.0K | $61.7K | — | $40.3M | $276M |
| Gross margin | -63.6% | 65.1% | 7.7% | -31.8% | 14.4% | 22.0% | 94.3% | — | 92.7% | 88.5% |
| Operating income | -$24.8M | -$32.9M | -$26.9M | -$21.0M | -$27.2M | -$29.4M | -$30.6M | -$49.0M | -$22.4M | $150M |
| Operating margin | -11048.8% | -9997.4% | -6250.4% | -7416.3% | -11378.4% | -15417.5% | -46819.9% | — | -51.4% | 48.2% |
| Net income | -$24.6M | -$33.0M | -$26.8M | -$16.4M | -$22.0M | -$28.2M | -$29.7M | -$46.3M | -$17.9M | $163M |
| Net margin | -10996.5% | -10023.4% | -6242.4% | -5801.3% | -9207.7% | -14774.7% | -45409.9% | — | -41.2% | 52.3% |
| EPS (diluted) | -$0.65 | -$0.60 | -$1.51 | -$1.80 | -$0.77 | -$0.75 | -$0.74 | -$0.91 | -$0.30 | $2.04 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.3M | -$28.6M | -$23.7M | -$15.1M | -$22.0M | -$21.2M | -$24.4M | -$38.4M | -$50.6M | $175M |
| Capital expenditures | $58.7K | $152K | $48.9K | $36.6K | $113K | $1.43M | $219K | $327K | $116K | $2.26M |
| Free cash flow | -$22.3M | -$28.7M | -$23.7M | -$15.1M | -$22.1M | -$22.6M | -$24.6M | -$38.7M | -$50.7M | $173M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8.06M | $10.4M | $17.6M | $16.4M | $41.9M | $53.3M | $43.1M | $43.6M | $40.7M | $145M |
| Total assets | $21.9M | $13.5M | $18.8M | $29.5M | $49.3M | $68.9M | $62.0M | $82.1M | $119M | $826M |
| Total liabilities | $4.09M | $6.26M | $13.9M | $5.83M | $5.09M | $6.15M | $6.98M | $11.9M | $34.2M | $421M |
| Shareholders' equity | $17.8M | $7.19M | $4.93M | $23.6M | $44.2M | $62.8M | $55.1M | $70.1M | $84.7M | $405M |
| Retained earnings | -$119M | -$152M | -$179M | -$195M | -$217M | -$246M | -$275M | -$322M | -$340M | -$177M |
| Shares (wtd avg diluted) | 40.4M | 71.4M | 21.8M | 25.7M | 33.6M | 37.7M | 40.3M | 50.9M | 58.9B | 80.3B |
Every figure is extracted from CorMedix Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.